A recent study suggests that patients who discontinue new GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight much more quickly than those who halt conventional lifestyle programs.
Findings released in a leading health publication points out that while overweight individuals frequently drop a large proportion of their total mass while using the jabs, the weight comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"People purchasing such medications need to be cognizant of the danger of quick weight regain when the treatment is stopped," warns expert Dr. Susan Jebb.
Such speed of recovery implies a return to pre-treatment mass in about 18 months.
Comparing Approaches
The study, which examined 37 of studies involving over 9,000 of patients, compared the results of GLP-1 agonists with other pills.
The team emphasize that people who lose weight through lifestyle changes alone typically experience a slower creep back—around 0.1 kg a month—once they finish.
The Reason for the Rapid Rebound
Nutrition scientists suggest the mode of action of the drugs accounts for the accelerated regain.
The injections copy a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Sustained high doses of the hormone concentrations far above than normal might result in the system to generate a reduced amount of its endogenous hormone, and may also lessen sensitivity to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this hormone supplement means appetite is unsuppressed, making binge eating much more probable."
A Chronic Disease?
Medical guidelines suggest the injections for people with obesity-related health risks, alongside recommended diet and exercise modifications.
Many experts say that, due to the likelihood of weight regain, the treatment is often long-term.
This perspective is supported by drug manufacturers, who say that the results "highlight the persistent nature of obesity," similar to managing conditions like diabetes.
User Testimonies
Users who have discontinued the jabs report a intense return of hunger.
"It was like something that goes on and you become starving," said one woman.
This challenge is worsened if users have not developed sustainable dietary or behavioural modifications during treatment.
Growing Interest
Figures show that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with demand continuing to grow.
- Adoption is greater among females compared to males.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion access the drugs through private healthcare rather than the NHS.
In conclusion, researchers caution that while GLP-1 drugs are potent tools for shedding pounds, they are not a permanent cure and long-term success likely depends on integrated lifestyle support.
